AbbVie price target raised to $190 from $188 at Guggenheim

Guggenheim raised the firm’s price target on AbbVie to $190 from $188 and keeps a Buy rating on the shares. The firm published revised versions of its large cap biopharmaceuticals company models after incorporating various recent updates and their recent 10-K filings. For AbbVie, the firm’s model now accounts for the close of the $10.1B ImmunoGen acquisition, including management’s updated Q1 EPS guidance that incorporates 4c of dilution from that deal, the analyst noted.